The Anti-Allodynic Effects of Amitriptyline, Gabapentin, and Lidocaine in a Rat Model of Neuropathic Pain

Abdi, Salahadin; Lee, Doo Hyun; Chung, Jin Mo

doi:10.1213/00000539-199812000-00027

Cited by 227 publications

(90 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Similarly, hindpaw mechanical allodynia was robustly reversed by gabapentin in both CCI and SNL rats Abdi et al 1998;Field et al 2002;Luo et al 2002).…”

Section: Discussionmentioning

confidence: 81%

Anti-nociception is selectively enhanced by parallel inhibition of multiple subtypes of monoamine transporters in rat models of persistent and neuropathic pain

2005

View full text Add to dashboard Cite

show abstract

“…Similarly, hindpaw mechanical allodynia was robustly reversed by gabapentin in both CCI and SNL rats Abdi et al 1998;Field et al 2002;Luo et al 2002).…”

Section: Discussionmentioning

confidence: 81%

Anti-nociception is selectively enhanced by parallel inhibition of multiple subtypes of monoamine transporters in rat models of persistent and neuropathic pain

2005

View full text Add to dashboard Cite

show abstract

“…Preclinical data in animal models of neuropathic pain showed strong evidence of gabapentin's efficacy [27] and also showed the superiority of gabapentin over other anticonvulsants, such as carbamazepine [28], and over felbamate and lamotrigine [12]. The benefits seen in animal models have been extrapolated to humans, with pilot studies corroborating the usefulness of gabapentin The cost of gabapentin, even at moderate doses, can be very high.…”

Section: Anticonvulsantsmentioning

confidence: 99%

Neurologic complications of cancer therapy

1999

Curr Treat Options Neurol

View full text Add to dashboard Cite

Although progress in cancer research is paralleled by the discovery and development of novel chemotherapeutic agents, the benefits of these agents are offset by their side-effect profiles. Of the numerous adverse effects associated with antineoplastic drugs, peripheral neuropathy is the most frequent and is often debilitating. This article reviews the treatment options--both primary and secondary--for neuropathic complications of cancer therapy. Before a potentially neurotoxic chemotherapeutic regimen is started, patients should undergo 1) a baseline neurologic history for possible coexisting risk factors for neuropathy; 2) physical evaluation; and 3) if indicated, electrophysiologic testing, including nerve conduction studies and electromyography. Patients should be followed closely for the development of neuropathic signs and symptoms. When symptoms (eg, paresthesias or pain) or deficits (eg, weakness) develop, their severity and their effect on quality of life will determine whether the neurotoxic chemotherapy should be continued at a lower dose or discontinued. Neuropathic pain should be treated aggressively with a stepwise approach. The decision to initiate therapy should be guided first by the severity of pain and second by the convenience of dosing and the side-effect profile of the medication. Specific antineuropathic pain therapy may begin with a tricyclic antidepressant (TCA), titrated to 100 to 150 mg/d, unless anticholinergic side effects appear before this dosage is reached. The TCA may be replaced by or supplemented with antiepileptic agents, such as gabapentin, which is attractive because of its rapid dose titration (maximum, 3600 mg/d) and minimal interaction with other medications. In addition to pharmacologic therapies targeting symptom management, new therapies directed at preventing the onset or progression of neurotoxicity are desperately needed.

show abstract

“…There is evidence for a possible effect of GBP on α2-δ calcium channels, which could explain its pain relieving effect [26]. In addition to its central allodynic effect [1], GBP has also been shown to inhibit ectopic discharge activity from injured nerves [18]. GBP, with its low adverse effect and drug interaction profile, may offer an effective treatment for neuropathic pain in HIV-infected patients.…”

Section: Introductionmentioning

confidence: 99%

A placebo-controlled trial of gabapentin for painful HIV-associated sensory neuropathies

et al. 2004

View full text Add to dashboard Cite

show abstract

The Anti-Allodynic Effects of Amitriptyline, Gabapentin, and Lidocaine in a Rat Model of Neuropathic Pain

Cited by 227 publications

References 26 publications

Anti-nociception is selectively enhanced by parallel inhibition of multiple subtypes of monoamine transporters in rat models of persistent and neuropathic pain

Anti-nociception is selectively enhanced by parallel inhibition of multiple subtypes of monoamine transporters in rat models of persistent and neuropathic pain

Neurologic complications of cancer therapy

A placebo-controlled trial of gabapentin for painful HIV-associated sensory neuropathies

Contact Info

Product

Resources

About